Senvest Management LLC Buys 22,300 Shares of uniQure N.V. $QURE

Senvest Management LLC lifted its stake in uniQure N.V. (NASDAQ:QURE) by 44.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 72,300 shares of the biotechnology company’s stock after purchasing an additional 22,300 shares during the period. Senvest Management LLC owned 0.11% of uniQure worth $1,182,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Siren L.L.C. acquired a new position in shares of uniQure during the first quarter valued at $16,350,000. Militia Capital Management LLC bought a new position in uniQure during the 1st quarter worth approximately $1,540,000. Sigma Planning Corp bought a new position in shares of uniQure during the first quarter worth $276,000. Stephens Inc. AR bought a new position in uniQure during the first quarter worth about $182,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of uniQure by 148.9% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 113,952 shares of the biotechnology company’s stock valued at $1,863,000 after purchasing an additional 68,174 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Trading Down 1.2%

Shares of uniQure stock opened at $38.97 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The business has a fifty day simple moving average of $35.94 and a two-hundred day simple moving average of $25.66. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -11.20 and a beta of 0.90.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Research analysts forecast that uniQure N.V. will post -3.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on QURE. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a research report on Tuesday, May 5th. Mizuho upped their target price on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. HC Wainwright boosted their price objective on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Royal Bank Of Canada increased their target price on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $64.17.

Insider Activity at uniQure

In other news, insider Walid Abi-Saab sold 30,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the transaction, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. This trade represents a 16.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total value of $982,995.48. Following the sale, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. The trade was a 44.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 433,229 shares of company stock valued at $17,944,799. 4.65% of the stock is currently owned by insiders.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.